• Home
  • 2019 VISION
  • LPBI Group
  • LPBI Group News
  • Medical 3D Printing
  • HealthCare INVESTOR’s Corner ($)
  • Journal PharmaceuticalIntelligence.com
  • BioMed e-Series
  • Press Coverage
  • Investor Relations
  • Our TEAM
  • Founder
  • Funding, Deals & Partnerships
  • Praising LPBI
  • CALENDAR
  • Contact Us
  • DrugDiscovery @LPBI Group
Advertisements

Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Funding, Deals & Partnerships: BIOLOGICS & MEDICAL DEVICES; BioMed e-Series; Medicine and Life Sciences Scientific Journal – http://PharmaceuticalIntelligence.com

Feeds:
Posts
Comments

Subsidiary 2: Deals, Funding & Partnerships – DFP

SUBSIDIARY #2

DFP

  • GDE – Deals, Funding and Partnerships – Early Stage Start Ups in need for funding: Biologics, Small Molecules, Diagnostics and Medical Devices

https://pharmaceuticalintelligence.com/joint-ventures/ 

HQS – Boston, MA

HQS – Lausanne, Switzerland, Gerard Loiseau, ESQ – Business Development

  • Corporate Clients for our Services
  • Funding Cardiovascular Medical Devices Development
  • Funding Biologics Development
  • Funding Diagnostics
  • Funding Partnerships in IP Development
  • M&A and Exit
  • Targeting Penetration in New Markets for High Technology Products
  • Modeling the Management of Intellectual Property Royalties

SIX TYPES of Investments are representing Business Opportunities in Subsidiary #2

1. Investment in the form of Seed Money to develop a Product Concept

Ongoing Projects:

1.1 Dr. Rosalind Codrington, Cambridge, UK,  Diagnostics Kit for Skin Cancer

1.2 Every Product concept of Dr. Justin D Pearlman

For M3DP – TWO inventions

1.2.1 A Product Concept to StopMI

1.2.2 A Product Concept for a Robotic Glove

For Joint Venture: SBH & M3DP – he has TWO inventions

1.2.3 A Product Concept for a “Cell BioFactory” for Diabetes

1.2.4 A Product Concept for an Artificial Kidney

1.3 Three Medical (Cardiovascular) Product Concept with US Patents issued to Bill Zurn, for Commercialization we requests $10Million, $10Million and $22Million

2. Investment in milestones for Products in Pre-Clinical Trials

2.1 ValveCure, Transition from Animal Trials to Human Trials or M&A

2.2 BioTerm Therapeutics (Dr. Shamir) – two drug-devices in OBGYN: Biologics and Multi needle circular syringe 

2.2.1 prevent early delivery

2.2.2 induce early Labor

2.3 Telerescue (Dr. Shamir) a defibrillator, wearable Digital Medical Device for arrhythmia 

2.4 Woodland Pharmaceuticals (Dr. Briggs and Dr. Raphael Nir) development of Biologics for

2.4.1 Brain Cancer, Multiform Gliomas

2.4.2 Liver Cancer: Anti Liver Fibrosis 

3. Investment in milestones for Start Ups in Clinical Trials Phase

4. Investment in U.S. AND INTERNATIONAL PATENTS

4.1 Three U.S. Patents of Dr. Pearlman issued PRIOR to affiliation with LPBI

4.2 Three Medical U.S. Patents of Bill Zurn

4.3 All Other non-Medical U.S. Patents of Bill Zurn

5. Sales Outright – Acquisition of a Platform Informational Systems

5.1 New Medicine/OncologyKnowledgeBase – Global Relational Database Oncology Drugs and Clinical Trials, the one and ONLY in existence in Private Ownership

https://pharmaceuticalintelligence.com/joint-ventures/ma-and-exit/leaders-in-pharmaceutical-business-intelligence-and-new-medicine-inc/

6. Investment in a PROFITABLE U.S. Biotech company

6.1 SBH Sciences, Inc. CEO and Owner, Dr. Raphael Nir, 10$ Sales Annually seeking $15Million investment for three Ventures, as follows:

1. SBH

http://www.sbhsciences.com/

Dr. Raphael Nir, CEO, Founder and Chairman

It is more accurate to “call” it : Galectin Sciences. It is a JV: SBH Sciences has 50% and Galactin Therapeutics has 50%.
The indication : Liver Fibrosis (NASH) : I assume $5M will advance us to IND.

  • Automatics Western Blot capabilities.

We have perform the following (9 case studies with all the data at: http://www.sbhdiagnostics.com/Simple_Western_Studies.asp):

  • Drug Effect On Protein Phosphorylation
  • Characterization Of Biotherapeutics
  • Drug Response Measurement
  • Identification Of Clinical Trial Patient Response
  • Monoclonal Antibody Analysis
  • Drug Response Time Course
  • Calculating Concentration of Unknown Biomarker
  • Optimization of Biomarker Recovery
  • Knockdown Experiment Using siRNA

 

2. Woodland Pharmaceuticals

http://woodlandbiosciences.com/Partners.asp

Dr. Raphael Nir, Co-Founder & CEO SBH Sciences
Woodland Biosciences is a strategic alliance between SBH Sciences, Woodland Pharmaceuticals and other partners, doing business as (DBA) Woodland Biosciences.
I assume $5M will advance us to IND for GBM.
We have also another indication : Pancreatic cancer . Similarly, $5M will advance us to IND.

We are seeking an Investment House to fund my Client-Companies

We are seeking to split my Finders Fee to get the funding accomplished

  • GDE – Deals, Funding and Partnerships – Private Equity for 20 Early Stage Start Ups: Biologics, Small Molecules and Medical Devices

 

Advertisements

Advertisements
  • Enter your email address to follow this blog and receive notifications of new posts by email.

    Join 2,434 other followers

  • Recent Posts

    • World Medical Innovation Forum, Partners Innovations, ARTIFICIAL INTELLIGENCE | APRIL 8–10, 2019 | Westin, BOSTON February 14, 2019
    • Drug Repurposing Hub Library @broadinstitute @MIT @Harvard February 14, 2019
    • Tumor Ammonia Recycling: How Cancer Cells Use Glutamate Dehydrogenase to Recycle Tumor Microenvironment Waste Products for Biosynthesis February 13, 2019
    • ‘Direct-to-Consumer (DTC) Genetic Testing Market to hit USD 2.5 Bn by 2024’ by Global Market Insights February 12, 2019
    • The Blavatnik Institute at Harvard Medical School’s 11 basic and social science departments launched in recognition of the transformative $200 million Blavatnik Family Foundation’s committed for scientific research  February 11, 2019
    • Newly Elect President of Technion, Professor Uri Sivan: Key Contributions to Scientific Innovations February 11, 2019
    • Blood sugar control after stroke February 7, 2019
    • Record Innovations in Drug Discovery by Koch Institute @MIT Members and Affiliates February 6, 2019
    • Gut bacteria can influence mood February 6, 2019
    • INFORMS talk “Impact of Bots on Opinions in Social Networks” Wed Feb 6 at MITRE in Bedford February 5, 2019
  • Archives

  • Categories

  • Meta

    • Register
    • Log in
    • Entries RSS
    • Comments RSS
    • WordPress.com
    • 2012pharmaceutical
    • Aashir Awan, Phd
    • Alan F. Kaul, PharmD., MS, MBA, FCCP
    • amnondanzig1724
    • anamikasarkar
    • apreconasia
    • aviralvatsa
    • David Orchard-Webb, PhD
    • danutdaagmailcom
    • Demet Sag, Ph.D., CRA, GCP
    • Dror Nir
    • evelinacohn
    • Gail S Thornton
    • Irina Robu
    • jdpmd
    • kellyperlman
    • Ed Kislauskis
    • larryhbern
    • lmulligan13gmailcom
    • marzankhan
    • megbaker58
    • pkandala
    • Rosalind Codrington, PhD
    • ritusaxena
    • Rick Mandahl
    • sjwilliamspa
    • stuartlpbi
    • Dr. Sudipta Saha
    • tildabarliya
    • zraviv06
    • zs22
  • Advertisements

Blog at WordPress.com.

WPThemes.